Journal of the American College of Cardiology
Clinical ResearchClinical TrialIncreased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes: Results of the SWAP (SWitching Anti Platelet) Study
Key Words
Abbreviations and Acronyms
Cited by (0)
The investigators and the centers participating in the SWAP study are listed in the Online Appendix. Financial support was provided by Daiichi Sankyo Inc. and by Eli Lilly and Company. Dr. Angiolillo reports receiving honoraria for lectures from Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, and Daiichi Sankyo; consulting fees from Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, Daiichi Sankyo, The Medicines Company, Portola, Novartis, Medicure, Accumetrics, Arena Pharmaceuticals, and AstraZeneca; and research grants from GlaxoSmithKline, Otsuka, Eli Lilly, Daiichi Sankyo, The Medicines Company, Portola, Accumetrics, Schering-Plough, AstraZeneca, Eisai, and Johnson & Johnson. Dr. Saucedo reports grant and research support from The Medicines Company, AstraZeneca, Abbott Vascular, Bristol-Myers Squibb, Medtronic, and Eli Lilly; and grant support, consulting fees, and honoraria from Schering-Plough. Dr. Frelinger reports grant and research support from Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, Daiichi Sankyo, and GLSynthesis; and consulting fees from Eli Lilly. Dr. Gurbel reports receiving honoraria for lectures from Sanofi-Aventis, AstraZeneca, Eli Lilly, Daiichi Sankyo, and Schering-Plough; consulting fees from Schering-Plough, AstraZeneca, Portola, Haemoscope, Sanofi, Pozen, and Bayer; and grant and research support from Schering-Plough, AstraZeneca, Portola, Haemoscope, and Bayer. Drs. Costigan, Jakubowski, Ojeh, and Effron are employees of and report equity ownership of or stock options in Eli Lilly. All other authors have reported that they have no relationships to disclose.